Company news

Medicus Pharma Ltd. (NASDAQ:MDCX) news

Medicus Pharma Ltd. news releases on 6ix. Latest, Sep 29, 2026: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner…

Medicus Pharma Ltd. (NASDAQ:MDCX) news

Press releases & updates

Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer

Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment

Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

Medicus Pharma Announces $22 Million Non-Dilutive Financing

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma To Participate in the 38th Annual Roth Conference

Medicus Pharma on Bloomberg World

New to The Street Signs Six-Part Media Series Featuring Medicus Pharma Ltd.

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome